![]() |
| Half of the participants received daily treatment with oral insulin, and the other half received placebo. Photo Credit: Kennet Ruona |
An international team of researchers has investigated whether oral insulin can prevent early signs of type 1 diabetes and clinical diagnosis in children with an increased risk of developing the disease. Although treatment with oral insulin could not prevent development of diabetes-related autoantibodies, oral insulin delayed the rate of disease progression in children who developed such autoantibodies. The results from the POInT study are now published in The Lancet.
The POInT study has investigated whether treatment with oral insulin can prevent diabetes-related autoantibodies and type 1 diabetes in children with an increased genetic risk of developing the disease. These autoantibodies are used as biomarkers for type 1 diabetes, and the presence of two or more autoantibodies is called early-stage type 1 diabetes. The international study includes 1,050 children from Sweden, Germany, Poland, Belgium and the United Kingdom. Half of the participants received daily treatment with oral insulin, and the other half received placebo during their first three years of life. In type 1 diabetes, the body’s immune system attacks the insulin-producing beta cells in the pancreas and destroys them.








.jpg)
